Is it time to use observational data to estimate treatment effectiveness in multiple sclerosis?

This publication has 12 references indexed in Scilit:

• How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
  Neurology, 2007
• New natural history of interferon‐β–treated relapsing multiple sclerosis
  Annals of Neurology, 2007
• The design versus the analysis of observational studies for causal effects: parallels with the design of randomized trials
  Statistics in Medicine, 2006
• How much can we learn from long-term extension trials in multiple sclerosis?
  Neurology, 2006
• Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS
  Neurology, 2006
• A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients
  Multiple Sclerosis Journal, 2006
• Readers guide to critical appraisal of cohort studies: 3. Analytical strategies to reduce confounding
  BMJ, 2005
• Association between Screening for Osteoporosis and the Incidence of Hip Fracture
  Annals of Internal Medicine, 2005
• Aspirin Use and All-Cause Mortality Among Patients Being Evaluated for Known or Suspected Coronary Artery Disease
  JAMA, 2001
• Placebo‐controlled clinical trials in multiple sclerosis: Ethical considerations
  Annals of Neurology, 2001